-
Lifecore Biomedical wins commercial manufacturing deal with global pharma firm
-
Lifecore and PolyPeptide partner for peptide manufacturing in US
-
Lifecore Biomedical (LFCR) files for $150M share and warrant offering
-
Lifecore Biomedical (LFCR) Misses Q2 EPS by 2c
-
Lifecore Biomedical (LFCR) Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer
-
Lifecore Biomedical (LFCR) Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale
-
Lifecore Biomedical (LFCR) Appoints Mark DaFonseca as Chief Commercial Officer
-
William Blair Starts Lifecore Biomedical (LFCR) at Outperform
-
Stephens Reiterates Equal Weight Rating on Lifecore Biomedical (LFCR)
-
Lifecore Biomedical (LFCR) Tops Q2 EPS by 2c
-
Lifecore Biomedical (LFCR) Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
-
Lifecore Biomedical (LFCR) Amends and Extends Revolving Credit Facility with BMO
-
Lifecore Biomedical (LFCR) PT Raised to $10 at Craig-Hallum
-
Lifecore Biomedical (LFCR) Appoints Thomas Guldager as Vice President, Operations
-
Lifecore Biomedical (LFCR) Files for 6.8M Share Offering by Selling Stockholders
-
Lifecore Biomedical (LFCR) PT Raised to $6 at Stephens
-
Stephens Reiterates Equal Weight Rating on Lifecore Biomedical (LFCR)
-
Lifecore Biomedical (LFCR) Reports Q1 Loss of $0.53/sh
-
Lifecore Biomedical (LFCR) Prices 5.93M Share Offering at $4.10/sh
-
Lifecore Biomedical (LFCR) Selected by Lindy Biosciences to Support Process Development and Commercial Scale-Up for Innovative Microglassification Formulation Technology
-
Lifecore Biomedical (LFCR) Regains Nasdaq Compliance
-
Lifecore Biomedical (LFCR) Announces CFO Transition

